On Thursday, Shares of EMC Corporation (NYSE:EMC), gained 0.17% to $24.17.
WANdisco, launched a 14 day free trial version of WANdisco Fusion allowing users to easily evaluate the technology on their own Apache Hadoop deployments.
Large organizations use WANdisco Fusion’s patented replication technology to achieve continuous availability and performance with guaranteed data consistency across Hadoop clusters any distance apart. With its flexible architecture, WANdisco Fusion can deliver these capabilities across clusters running on the same or different versions of a single Hadoop distribution, in addition to clusters running on mixed storage platforms counting Cloudera, Hortonworks (HDP), EMC (EMC) and MapR, completely eliminating vendor lock-in.
In most large global enterprises, Hadoop environments are in a constant state of change due to frequent hardware and software upgrades, the addition of clusters at new locations, the continual rollout of new applications, changes in usage patterns, data migration projects and never-ending demands for improved performance. All of these factors put noteworthy pressure on an organization’s big data infrastructure. Costly downtime and data loss are a frequent occurrence during any of these activities with the brittle solutions typically available. With WANdisco’s patented technology, the flexibility to dynamically bring servers and entire data centers online or offline, and redeploy them without losing access to applications or data during upgrades and migrations, is now a reality.
EMC Corporation develops, delivers, and supports information infrastructure and virtual infrastructure technologies, solutions, and services. It offers enterprise storage systems and software deployed in storage area networks (SAN), networked attached storage (NAS), unified storage combining NAS and SAN, object storage, and/or direct attached storage environments, in addition to provides a portfolio of backup products that support a range of enterprise application workloads.
Shares of Kroger Co (NYSE:KR), declined -0.20% to $34.58, during its last trading session.
Kroger Co., named Jessica C. Adelman to serve as Kroger’s group vice president of corporate affairs, effective November 1.
“Jessica brings a wealth of public affairs leadership experience and deep knowledge of the food supply chain,” said Rodney McMullen, Kroger’s chairman and chief executive officer. “We look forward to welcoming her to our senior leadership team.”
Ms. Adelman, 40, has 20 years of experience as a public affairs executive in the food industry, most recently as senior vice president of corporate affairs for Syngenta North America, a leading agriculture company, since 2008. In this role she was responsible for corporate brand oversight, government affairs, media relations, crisis and issues communications, litigation communications, internal communications and employee engagement, corporate social responsibility and giving. Ms. Adelman has held several planned leadership roles with other companies, counting director of Cargill Government Solutions.
The Kroger Co., together with its auxiliaries, operates as a retailer in the United States and internationally. It also manufactures and processes food for sale in its supermarkets. The company operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores.
Finally, Laboratory Corp. of America Holdings (NYSE:LH), ended its last trade with 0.98% gain, and closed at $117.52.
Laboratory Corporation of America Holdings, declared an expansion of its long-standing partnership with the Perinatal Quality Foundation (PQF) to collaborate on a new planned initiative focused on noninvasive prenatal screening, the Genetic Education Module (GEM).
PQF’s GEM initiative will provide education to assist patients and healthcare providers better understand the benefits and limitations of noninvasive prenatal screening and how to interpret the results of that screening. GEM will also build a patient registry designed to correlate the results of noninvasive prenatal testing with the results of confirmatory diagnostic tests, such as chorionic villus sampling (CVS) or amniocentesis, in addition to post-partum outcomes. In addition, the initiative will assist develop processes for credentialing healthcare personnel in the delivery of pre- and post- screening information. LabCorp and PQF are committed to improve patient outcomes and lives, while lowering costs, through expanded access to emerging healthcare technologies, such as their existing work on PQF’s Nuchal Translucency Quality Review program, which provides education and credentialing for sonographers and physicians involved in first trimester risk assessment.
“As new genetic technologies enter the market, it is imperative for industry leaders, such as LabCorp, to foster the use of genetic information and support the appropriate administration and interpretation of these technologies,” said Dr. Ron Wapner and Dr. Larry Platt, members of the PQF board of directors. “LabCorp is one of the founding supporters of PQF, and we welcome LabCorp’s continued assistance in assisting PQF meet its objectives of educating patients and providers.”
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
